HomeIMCR • NASDAQ
add
Immunocore Holdings PLC - ADR
Previous close
$53.29
Day range
$52.25 - $53.50
Year range
$42.21 - $76.98
Market cap
2.66B USD
Avg Volume
475.62K
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Revenue | 70.50M | 28.99% |
Operating expense | 39.29M | 20.63% |
Net income | -24.44M | -25.64% |
Net profit margin | -34.66 | 2.59% |
Earnings per share | -0.49 | -40.00% |
EBITDA | -25.48M | -85.38% |
Effective tax rate | -1.48% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 832.82M | 99.49% |
Total assets | 993.99M | 86.62% |
Total liabilities | 634.45M | 227.82% |
Total equity | 359.53M | — |
Shares outstanding | 50.01M | — |
Price to book | 7.41 | — |
Return on assets | -8.32% | — |
Return on capital | -10.31% | — |
Cash Flow
Net change in cash
| (USD) | Mar 2024info | Y/Y change |
|---|---|---|
Net income | -24.44M | -25.64% |
Cash from operations | -4.59M | -143.52% |
Cash from investing | -430.00K | 85.67% |
Cash from financing | 396.01M | 6,350.76% |
Net change in cash | 390.20M | 2,353.29% |
Free cash flow | 358.38K | -96.90% |
About
Immunocore is a global commercial-stage biotechnology company, based in Oxfordshire, which researches and develops biological drugs using soluble T-cell receptor technology. Wikipedia
Founded
2008
Website
Employees
497
